Search

Your search keyword '"Aimee M. Crago"' showing total 4 results
Start Over Author "Aimee M. Crago" Journal nature communications
4 results on '"Aimee M. Crago"'

1. Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets

Author

Benjamin A. Nacev, Francisco Sanchez-Vega, Shaleigh A. Smith, Cristina R. Antonescu, Evan Rosenbaum, Hongyu Shi, Cerise Tang, Nicholas D. Socci, Satshil Rana, Rodrigo Gularte-Mérida, Ahmet Zehir, Mrinal M. Gounder, Timothy G. Bowler, Anisha Luthra, Bhumika Jadeja, Azusa Okada, Jonathan A. Strong, Jake Stoller, Jason E. Chan, Ping Chi, Sandra P. D’Angelo, Mark A. Dickson, Ciara M. Kelly, Mary Louise Keohan, Sujana Movva, Katherine Thornton, Paul A. Meyers, Leonard H. Wexler, Emily K. Slotkin, Julia L. Glade Bender, Neerav N. Shukla, Martee L. Hensley, John H. Healey, Michael P. La Quaglia, Kaled M. Alektiar, Aimee M. Crago, Sam S. Yoon, Brian R. Untch, Sarah Chiang, Narasimhan P. Agaram, Meera R. Hameed, Michael F. Berger, David B. Solit, Nikolaus Schultz, Marc Ladanyi, Samuel Singer, and William D. Tap

Subjects
Science
Abstract

Sarcomas are rare tumours with many different subtypes and clinical outcomes; a broader knowledge of their genetic features is required. Here, the authors analyse 2138 soft tissue and bone sarcomas across 45 subtypes using MSK-IMPACT targeted sequencing and find genomic groups that are distinct from histological subgroups.

Published
2022
Full Text
View/download PDF

2. Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors

Author

Cristina Valero, Mark Lee, Douglas Hoen, Kate Weiss, Daniel W. Kelly, Prasad S. Adusumilli, Paul K. Paik, George Plitas, Marc Ladanyi, Michael A. Postow, Charlotte E. Ariyan, Alexander N. Shoushtari, Vinod P. Balachandran, A. Ari Hakimi, Aimee M. Crago, Kara C. Long Roche, J. Joshua Smith, Ian Ganly, Richard J. Wong, Snehal G. Patel, Jatin P. Shah, Nancy Y. Lee, Nadeem Riaz, Jingming Wang, Ahmet Zehir, Michael F. Berger, Timothy A. Chan, Venkatraman E. Seshan, and Luc G. T. Morris

Subjects
Science
Abstract

There is an unmet clinical need for simple, accessible biomarkers to select patients who are more likely to respond to immune checkpoint therapy. Here the authors show that a lower neutrophil-to-lymphocyte ratio is associated with better overall and progressive-free survival, as well as higher rate of response, in a multi-cancer cohort of patients treated with immune checkpoint inhibitors.

Published
2021
Full Text
View/download PDF

3. ATRX is a regulator of therapy induced senescence in human cells

Author

Marta Kovatcheva, Will Liao, Mary E. Klein, Nicolas Robine, Heather Geiger, Aimee M. Crago, Mark A. Dickson, William D. Tap, Samuel Singer, and Andrew Koff

Subjects
Science
Abstract

Therapy induced senescence (TIS) is a growth suppressive program activated by cytostatic agents in some cancer cells. Here the authors show that the chromatin remodeling enzyme ATRX is a regulator of TIS and drives cells into this state via multiple mechanisms.

Published
2017
Full Text
View/download PDF

4. Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors

Author

Luc G. T. Morris, Marc Ladanyi, Aimee M. Crago, Nadeem Riaz, Jingming Wang, Prasad S. Adusumilli, A. Ari Hakimi, George Plitas, Alexander N. Shoushtari, Kate Weiss, Snehal G. Patel, Ahmet Zehir, Douglas R. Hoen, Nancy Y. Lee, Michael A. Postow, J. Joshua Smith, Michael F. Berger, Ian Ganly, Charlotte E. Ariyan, Kara Long Roche, Cristina Valero, Vinod P. Balachandran, Mark Lee, Daniel Kelly, Venkatraman E. Seshan, Jatin P. Shah, Richard J. Wong, Paul K. Paik, and Timothy A. Chan

Subjects
0301 basic medicine, Oncology, Male, medicine.medical_specialty, Neutrophils, Science, General Physics and Astronomy, Cancer immunotherapy, Drug resistance, General Biochemistry, Genetics and Molecular Biology, Article, 03 medical and health sciences, 0302 clinical medicine, Mutation Rate, Predictive Value of Tests, Internal medicine, Neoplasms, Medicine, Humans, Progression-free survival, Lymphocyte Count, Lymphocytes, Neutrophil to lymphocyte ratio, Cancer genetics, Immune Checkpoint Inhibitors, Aged, Retrospective Studies, Multidisciplinary, business.industry, fungi, Cancer, Retrospective cohort study, General Chemistry, Translational research, Middle Aged, medicine.disease, Immune checkpoint, Progression-Free Survival, 030104 developmental biology, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Cohort, Biomarker (medicine), Tumour immunology, Female, business, Biomarkers, Follow-Up Studies
Abstract

Treatment with immune checkpoint inhibitors (ICI) has demonstrated clinical benefit for a wide range of cancer types. Because only a subset of patients experience clinical benefit, there is a strong need for biomarkers that are easily accessible across diverse practice settings. Here, in a retrospective cohort study of 1714 patients with 16 different cancer types treated with ICI, we show that higher neutrophil-to-lymphocyte ratio (NLR) is significantly associated with poorer overall and progression-free survival, and lower rates of response and clinical benefit, after ICI therapy across multiple cancer types. Combining NLR with tumor mutational burden (TMB), the probability of benefit from ICI is significantly higher (OR = 3.22; 95% CI, 2.26-4.58; P, There is an unmet clinical need for simple, accessible biomarkers to select patients who are more likely to respond to immune checkpoint therapy. Here the authors show that a lower neutrophil-to-lymphocyte ratio is associated with better overall and progressive-free survival, as well as higher rate of response, in a multi-cancer cohort of patients treated with immune checkpoint inhibitors.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results